← Back to Screener
Quanterix Corporation Common Stock (QTRX)
Price$3.30
Favorite Metrics
Price vs S&P 500 (26W)-46.69%
Price vs S&P 500 (4W)-27.72%
Market Capitalization$164.29M
All Metrics
Book Value / Share (Quarterly)$6.33
P/TBV (Annual)1.81x
Indicated Dividend (Annual)$0.00
Revenue Growth (3Y)9.60%
Cash Flow / Share (Quarterly)$-1.71
Price vs S&P 500 (YTD)-49.11%
Gross Margin (TTM)46.77%
Net Profit Margin (TTM)-77.14%
EPS (TTM)$-2.52
10-Day Avg Trading Volume0.89M
EPS Excl Extra (TTM)$-2.52
Revenue Growth (5Y)9.96%
EPS (Annual)$-2.51
ROI (Annual)-36.23%
Gross Margin (Annual)46.77%
Net Profit Margin (5Y Avg)-54.44%
Cash / Share (Quarterly)$2.53
Revenue Growth QoQ (YoY)24.73%
ROA (Last FY)-25.59%
Revenue Growth TTM (YoY)1.07%
EBITD / Share (TTM)$-2.46
ROE (5Y Avg)-19.20%
Operating Margin (TTM)-90.38%
Cash Flow / Share (Annual)$-1.71
P/B Ratio0.56x
P/B Ratio (Quarterly)1.00x
Net Income / Employee (Annual)$-0
EV / Revenue (TTM)0.97x
Net Interest Coverage (TTM)-143.25x
ROA (TTM)-26.21%
EPS Incl Extra (Annual)$-2.51
Current Ratio (Annual)2.84x
Quick Ratio (Quarterly)1.98x
3-Month Avg Trading Volume0.73M
52-Week Price Return-32.17%
Revenue / Employee (TTM)$0
Tangible BV / Share (Quarterly)$3.51
P/S Ratio (Annual)1.18x
Asset Turnover (Annual)0.33x
52-Week High$8.77
Operating Margin (5Y Avg)-63.13%
EPS Excl Extra (Annual)$-2.51
CapEx CAGR (5Y)-7.85%
Tangible BV CAGR (5Y)-3.15%
26-Week Price Return-37.94%
Quick Ratio (Annual)1.98x
13-Week Price Return-52.38%
Total Debt / Equity (Annual)0.00x
Current Ratio (Quarterly)2.84x
Enterprise Value$134.451
Revenue / Share Growth (5Y)2.22%
Asset Turnover (TTM)0.34x
Book Value / Share Growth (5Y)-0.48%
Revenue / Employee (Annual)$0
Inventory Turnover (Annual)1.69x
Pretax Margin (Annual)-80.83%
Cash / Share (Annual)$2.53
3-Month Return Std Dev68.42%
Gross Margin (5Y Avg)53.61%
Net Income / Employee (TTM)$-0
ROE (Last FY)-36.23%
Net Interest Coverage (Annual)-79.64x
EPS Basic Excl Extra (Annual)$-2.51
Receivables Turnover (TTM)4.47x
Total Debt / Equity (Quarterly)0.00x
EPS Incl Extra (TTM)$-2.52
Receivables Turnover (Annual)4.47x
ROI (TTM)-35.13%
P/S Ratio (TTM)1.18x
Pretax Margin (5Y Avg)-54.97%
Revenue / Share (Annual)$3.26
Tangible BV / Share (Annual)$3.51
Price vs S&P 500 (52W)-67.27%
Year-to-Date Return-44.97%
5-Day Price Return3.24%
EPS Normalized (Annual)$-2.51
ROA (5Y Avg)-15.09%
Net Profit Margin (Annual)-77.14%
Month-to-Date Return-0.57%
Cash Flow / Share (TTM)$-0.87
EBITD / Share (Annual)$-2.46
Operating Margin (Annual)-90.38%
LT Debt / Equity (Annual)0.00x
ROI (5Y Avg)-19.20%
LT Debt / Equity (Quarterly)0.00x
EPS Basic Excl Extra (TTM)$-2.52
P/TBV (Quarterly)1.81x
P/B Ratio (Annual)1.00x
Inventory Turnover (TTM)1.69x
Pretax Margin (TTM)-80.83%
Book Value / Share (Annual)$6.33
Price vs S&P 500 (13W)-55.25%
Beta1.23x
Revenue / Share (TTM)$2.97
ROE (TTM)-35.16%
52-Week Low$3.23
Analyst Recommendations
Jan 2026
Feb 2026
Mar 2026
Apr 2026
2.44
2.44
2.44
2.44
Industry Peers — Lab Analytical Instruments(22)
| Symbol | P/S Ratio (TTM) | Revenue Growth (5Y) | Gross Margin (TTM) | Operating Margin (TTM) | Price |
|---|---|---|---|---|---|
QTRXQuanterix Corporation Common Stock | 1.18x | 9.96% | 46.77% | -90.38% | $3.30 |
AAgilent Technologies Inc. | 4.83x | 5.41% | 52.60% | 20.40% | $120.96 |
WATWaters Corp | 10.18x | 6.00% | 59.28% | 25.36% | $335.61 |
MTDMettler-Toledo International | 6.66x | 5.47% | 59.37% | 26.05% | $1324.66 |
ILMNIllumina Inc | 4.69x | 6.04% | 66.61% | 18.44% | $132.86 |
RVTYRevvity, Inc. | 3.64x | -5.46% | 54.77% | 12.49% | $93.03 |
BIOBio-Rad Laboratories, Inc.Class A | 3.17x | 0.29% | 52.01% | 1.59% | $303.34 |
BIO.BBio-Rad Laboratories, Inc. Class B | 3.17x | 0.29% | 52.01% | 1.59% | $277.00 |
BRKRBruker Corporation | 1.81x | 11.57% | 47.13% | 1.40% | $41.10 |
BRKRPBruker Corporation 6.375% Mandatory Convertible Preferred Stock, Series A | 1.81x | 11.57% | 47.13% | 1.40% | $320.13 |
AVTRAvantor, Inc. | 0.88x | 0.49% | 32.65% | -3.83% | $8.50 |
About
Quanterix Corp develops ultra-sensitive digital immunoassay platforms that detect protein biomarkers at concentrations undetectable by conventional technologies. The company's Simoa platform enables precision diagnostics and life sciences research across multiple therapeutic areas, supported by a suite of instruments, assays, and laboratory services. With a global presence spanning North America, EMEA, and Asia Pacific, Quanterix serves the growing market for advanced biomarker detection in healthcare and research.